A Cancer Research Campaign (CRC) phase II trial of CB10-277 given by 24 hour infusion for malignant melanoma.

The decarbazine analogue CB10-277 has been investigated for anti-tumour activity in a phase II study on malignant melanoma. Treatment was administered as a slow infusion of 12,000 mg m-2 over 24 h and repeated every 3 weeks. A total of 28 patients were entered into the study, of whom 23 were eligibl...

Descripción completa

Detalles Bibliográficos
Autores principales: Bleehen, N. M., Calvert, A. H., Lee, S. M., Harper, P., Kaye, S. B., Judson, I., Brampton, M.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1994
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2033397/
https://www.ncbi.nlm.nih.gov/pubmed/7917939
_version_ 1782136829148921856
author Bleehen, N. M.
Calvert, A. H.
Lee, S. M.
Harper, P.
Kaye, S. B.
Judson, I.
Brampton, M.
author_facet Bleehen, N. M.
Calvert, A. H.
Lee, S. M.
Harper, P.
Kaye, S. B.
Judson, I.
Brampton, M.
author_sort Bleehen, N. M.
collection PubMed
description The decarbazine analogue CB10-277 has been investigated for anti-tumour activity in a phase II study on malignant melanoma. Treatment was administered as a slow infusion of 12,000 mg m-2 over 24 h and repeated every 3 weeks. A total of 28 patients were entered into the study, of whom 23 were eligible for review. A total of 64 courses was given. There was one objective partial response in 22 patients assessable for response. The major toxicities were leucopenia and thrombocytopenia. CB10-277 in this schedule therefore does not appear to have major activity in melanoma.
format Text
id pubmed-2033397
institution National Center for Biotechnology Information
language English
publishDate 1994
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-20333972009-09-10 A Cancer Research Campaign (CRC) phase II trial of CB10-277 given by 24 hour infusion for malignant melanoma. Bleehen, N. M. Calvert, A. H. Lee, S. M. Harper, P. Kaye, S. B. Judson, I. Brampton, M. Br J Cancer Research Article The decarbazine analogue CB10-277 has been investigated for anti-tumour activity in a phase II study on malignant melanoma. Treatment was administered as a slow infusion of 12,000 mg m-2 over 24 h and repeated every 3 weeks. A total of 28 patients were entered into the study, of whom 23 were eligible for review. A total of 64 courses was given. There was one objective partial response in 22 patients assessable for response. The major toxicities were leucopenia and thrombocytopenia. CB10-277 in this schedule therefore does not appear to have major activity in melanoma. Nature Publishing Group 1994-10 /pmc/articles/PMC2033397/ /pubmed/7917939 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Bleehen, N. M.
Calvert, A. H.
Lee, S. M.
Harper, P.
Kaye, S. B.
Judson, I.
Brampton, M.
A Cancer Research Campaign (CRC) phase II trial of CB10-277 given by 24 hour infusion for malignant melanoma.
title A Cancer Research Campaign (CRC) phase II trial of CB10-277 given by 24 hour infusion for malignant melanoma.
title_full A Cancer Research Campaign (CRC) phase II trial of CB10-277 given by 24 hour infusion for malignant melanoma.
title_fullStr A Cancer Research Campaign (CRC) phase II trial of CB10-277 given by 24 hour infusion for malignant melanoma.
title_full_unstemmed A Cancer Research Campaign (CRC) phase II trial of CB10-277 given by 24 hour infusion for malignant melanoma.
title_short A Cancer Research Campaign (CRC) phase II trial of CB10-277 given by 24 hour infusion for malignant melanoma.
title_sort cancer research campaign (crc) phase ii trial of cb10-277 given by 24 hour infusion for malignant melanoma.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2033397/
https://www.ncbi.nlm.nih.gov/pubmed/7917939
work_keys_str_mv AT bleehennm acancerresearchcampaigncrcphaseiitrialofcb10277givenby24hourinfusionformalignantmelanoma
AT calvertah acancerresearchcampaigncrcphaseiitrialofcb10277givenby24hourinfusionformalignantmelanoma
AT leesm acancerresearchcampaigncrcphaseiitrialofcb10277givenby24hourinfusionformalignantmelanoma
AT harperp acancerresearchcampaigncrcphaseiitrialofcb10277givenby24hourinfusionformalignantmelanoma
AT kayesb acancerresearchcampaigncrcphaseiitrialofcb10277givenby24hourinfusionformalignantmelanoma
AT judsoni acancerresearchcampaigncrcphaseiitrialofcb10277givenby24hourinfusionformalignantmelanoma
AT bramptonm acancerresearchcampaigncrcphaseiitrialofcb10277givenby24hourinfusionformalignantmelanoma
AT bleehennm cancerresearchcampaigncrcphaseiitrialofcb10277givenby24hourinfusionformalignantmelanoma
AT calvertah cancerresearchcampaigncrcphaseiitrialofcb10277givenby24hourinfusionformalignantmelanoma
AT leesm cancerresearchcampaigncrcphaseiitrialofcb10277givenby24hourinfusionformalignantmelanoma
AT harperp cancerresearchcampaigncrcphaseiitrialofcb10277givenby24hourinfusionformalignantmelanoma
AT kayesb cancerresearchcampaigncrcphaseiitrialofcb10277givenby24hourinfusionformalignantmelanoma
AT judsoni cancerresearchcampaigncrcphaseiitrialofcb10277givenby24hourinfusionformalignantmelanoma
AT bramptonm cancerresearchcampaigncrcphaseiitrialofcb10277givenby24hourinfusionformalignantmelanoma

Ejemplares similares